Recent Omicron-Related COVID-19 Surge Fuels Demand For Biotia’s COVID-DX Amongst Researchers And Public Health Authorities
Biotia, Inc., a health-tech company in Brooklyn, NY, is building the leading microbial sequencing database coupled with AI software for precision infectious disease detection and diagnosis. Since the onset of the COVID-19 pandemic, Biotia has been developing innovative software and diagnostic technologies to provide researchers and public health authorities the tools to fight the spread of SARS-CoV-2 and its variants.
“At Biotia, we support rapid public health responses to the continuously evolving SARS-CoV-2 virus. Our COVID-DX software produces actionable reporting that supports genomic surveillance of Omicron and other Delta-like variants, while informing regulatory agencies to prevent further spread and control the pandemic”, says Dr. Dorottya Nagy-Szakal, Chief Medical Officer at Biotia.
COVID-DX, Biotia’s FDA vetted, commercial grade software platform provides comprehensive variant profiling of SARS-CoV-2, including Omicron. The platform has seen strong adoption by clinical researchers worldwide due to its user-friendly portal, powerful reporting, and versatility. "We built COVID-DX to enable researchers to seamlessly incorporate rapidly emerging new variants into their analysis" says Dr. David Danko, Director of Bioinformatics at Biotia.
Operating out of their Brooklyn-based CLIA lab, Biotia offers a complete solution for COVID-19 testing including rapid diagnostics, sequencing services, and software analytics. For more information, please visit biotio.io/coviddx.
DISCLAIMER: COVID-DX bioinformatic tools are research use only (RUO) and are not intended to provide diagnostic results or guide treatment of patients. The RUO report has not been approved by the FDA, nor is it required to be. The Biotia Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88) and is accredited to perform high-complexity clinical laboratory testing.
About Biotia
Biotia is a health-tech company located in New York, NY, that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious diseases by deploying the leading reference library of microbes worldwide. As a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech, Biotia has a New York State CLIA lab for infectious disease diagnostics testing affiliated with SUNY Downstate Health Sciences University.